L-Chicoric Acid ((-)-Chicoric acid) is a dicaffeoyltartaric acid and a potent, selective and reversible HIV-1 integrase inhibitor with an IC₅₀ of ~100 nM. L-Chicoric Acid inhibits HIV-1 replication in tissue culture^[1][2][3].

IC50: ~100 nM (HIV-1 integrase)^[1][2]
HIV-1^[2]

L-Chicoric Acid inhibits integration at concentrations from 500 nM to 10 μM but also inhibits entry at concentrations above 1 μM. L-Chicoric Acid clearly affects viral entry at concentrations of 5 μM and higher. L-Chicoric Acid also inhibits integration as indicated both by an increased ratio of two LTR circle DNA to cDNA and an accompanying decrease in integrated provirus. The EC₅₀ of L-Chicoric Acid against HIV is approximately 500 nM, a concentration that does not inhibit HIV entry in H9 cells^[1].
The ED₅₀ of L-Chicoric Acid against HIV_NL4-3 control virus is 400 nM, while HIV_NL4-3 passaged in the presence of 8 μM L-Chicoric Acid is completely resistant to the compound^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

474.37

C₂₂H₁₈O₁₂

70831-56-0

L-菊苣酸

Room temperature in continental US; may vary elsewhere.

-20°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

In Vitro: 

DMSO : 100 mg/mL (210.81 mM; Need ultrasonic)

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

  Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (5.27 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

  Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (5.27 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90% corn oil

  Solubility: ≥ 2.5 mg/mL (5.27 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (5.27 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

• [1]. Reinke RA, et al. L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro. Virology. 2004 Sep 1;326(2):203-19.

  [2]. King PJ, et al. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol. 1998 Oct;72(10):8420-4.

  [3]. Robinson WE Jr. L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of a protease inhibitor (AG1350). Antiviral Res. 1998 Aug;39(2):101-11.